Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

(2021) R. Scott Wright et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review

(2020) Eric Bruckert et al.   ADVANCES IN THERAPY

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association

(2019) Mark McClellan et al.   CIRCULATION

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels

(2019) Kausik K. Ray et al.   JAMA Cardiology

Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9

(2019) Charles A. German et al.   BIODRUGS

Inclisiran—New hope in the management of lipid disorders?

(2019) Krzysztof Dyrbuś et al.   Journal of Clinical Lipidology

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

(2019) R. Scott Wright et al.   MAYO CLINIC PROCEEDINGS

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression

(2018) Jennifer L.S. Willoughby et al.   MOLECULAR THERAPY

Reprint of: Impact of Lipids on Cardiovascular Health

(2018) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Gregory A Roth et al.   LANCET

Inhibiting PCSK9 — biology beyond LDL control

(2018) Robert M. Stoekenbroek et al.   Nature Reviews Endocrinology

Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs

(2017) Anastasia Khvorova   NEW ENGLAND JOURNAL OF MEDICINE

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

(2017) Christopher P. Cannon et al.   JAMA Cardiology

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

(2016) John P. Gibbs et al.   JOURNAL OF CLINICAL PHARMACOLOGY

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

(2015) Terry A. Jacobson et al.   Journal of Clinical Lipidology

An assessment by the Statin Liver Safety Task Force: 2014 update

(2014) Harold Bays et al.   Journal of Clinical Lipidology

Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis

(2013) Daniel Urban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010

(2012) Kate Smolina et al.